See What HealthDay Can Do For You
Contact Us

ACC/AHA Risk Score No Better for Identifying Elevated CAC in RA

Ten-year risk score no better than Framingham Risk Score, Reynolds Risk Score

TUESDAY, Feb. 10, 2015 (HealthDay News) -- For patients with rheumatoid arthritis (RA), the 2013 American College of Cardiology/American Heart Association (ACC/AHA) 10-year risk score does not improve identification of those with elevated cardiovascular risk based on high coronary artery calcification (CAC) scores, according to a study published in the February issue of Arthritis & Rheumatology.

Vivian K. Kawai, M.D., M.P.H., from the Vanderbilt University School of Medicine in Nashville, Tenn., and colleagues compared the 10-year Framingham Risk Score (FRS), Reynolds Risk Score (RRS), and ACC/AHA risk score for identifying patients with RA known to have elevated cardiovascular risk based on high CAC scores. Of 98 patients eligible for risk stratification using the ACC/AHA risk score, 34 were identified with high CAC.

The researchers found that patients with high CAC had higher scores with all three risk scores (P < 0.05). For all three risk scores, the percentage of patients with high CAC who were correctly assigned to the elevated risk category was similar: FRS, 32 percent; RRS, 32 percent; and ACC/AHA, 41 percent (P = 0.223). The C-statistics for predicting the presence of elevated CAC were 0.65 for FRS, 0.66 for RRS, and 0.65 for ACC/AHA.

"The ACC/AHA 10-year risk score does not offer any advantage compared to the traditional FRS and RRS in the identification of RA patients with elevated risk as determined by high CAC," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.